Breaking News, Collaborations & Alliances

LIfT BioSciences, Minaris Regenerative Enter Cell Therapy Partnership

The two companies will develop a GMP-compliant manufacturing process to supply LIfT’s clinical trial programs in Europe.

LIfT BioSciences, a pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a global contract development and manufacturing organization (CDMO) provider for the cell and gene therapy industry, have formed a partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based leukocyte infusion therapy for the treatment of various cancer indications, including pancreatic cancer, lung can...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters